RecruitingPhase 1Phase 2NCT05766748

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Sponsor

Cantex Pharmaceuticals

Enrollment

30 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Pancreatic Cancer

Summary

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug called azeliragon in patients with locally advanced or metastatic pancreatic cancer that has stopped responding to prior chemotherapy. Azeliragon targets a protein involved in cancer cell survival and inflammation. **You may be eligible if...** - You have confirmed locally advanced or metastatic pancreatic cancer (adenocarcinoma) - You have previously been treated with gemcitabine/Abraxane or FOLFIRINOX-based chemotherapy - You are between 18 and 80 years old - You have recovered from prior treatment side effects - You have adequate organ function **You may NOT be eligible if...** - You have not had prior chemotherapy for pancreatic cancer - You have ongoing serious side effects from previous treatment - You are pregnant or breastfeeding - You have poor organ function Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAzeliragon

Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.